Dr. Rojas-Quintero is researching how Metformin, a long-used diabetes drug, may be able to slow fibrosis in the lungs.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio November 20 marks World COPD Day 2024, a ...

Christopher Carlin, MB ChB, PhD, explores the potential of AI-driven insights to enhance COPD care and identify candidates for biologic therapy.

The biologic dosed every 2 weeks reduced moderate or severe COPD exacerbations over 52 weeks by a relative 15.4% compared ...

A phase 3 trial evaluating benralizumab for the treatment of COPD did not meet its primary endpoint, according to AstraZeneca.

A Phase 3 clinical trial testing benralizumab as a potential treatment in COPD patients has failed to meet its main goal.

The effect of chronic breathlessness on the lives of patients and their loved ones is tremendous, regardless of the ...

Please provide your email address to receive an email when new articles are posted on . This analysis spanned from 2016 to 2022. Nearly 50% of patients were initially prescribed LABA/inhaled ...

AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil counts ...